MyFinsight

HomeCompareBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

Scribe Therapeutics, Inc. (SCTX)

Scribe Therapeutics, Inc. (SCTX)

||
||

Cash Flow Overview

Free Cash flow
-$12,919K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Maturities of investments
    • Receivables from collaboration p...
    • Cash received from government gr...
    • Others
Negative Cash Flow Breakdown
    • Purchases of investments
    • Accruals and other current liabi...
    • Accounts payable
    • Others
Cash Flow
2026-06-30
Net loss
-23,824
Depreciation expense
1,277
Loss on disposal of equipment
-4
Stock-based compensation expense
2,197
Interest expense
875
Change in fair value of convertible note
1,585
Net amortization/accretion on investment securities
-210
Amortization of right-of-use asset
281
Expensed deferred offering costs
0
Cash received from government grants
3,830
Receivables from collaboration partners
-5,985
Prepaid expenses and other current assets
-890
Other long-term assets
520
Accounts payable
-2,139
Deferred revenue
-1,850
Accrued license fees
1,725
Accruals and other current liabilities
-3,236
Operating lease liabilities
-616
Other non-current liabilities
434
Net cash used in operating activities
-12,892
Purchases of property and equipment
27
Maturities of investments
42,339
Purchases of investments
4,842
Net cash provided by investing activities
37,470
Proceeds from exercise of stock options
238
Payments of deferred offering costs
2,026
Net cash (used in) / provided by financing activities
-1,788
Net change in cash, cash equivalents and restricted cash
22,790
Cash, cash equivalents and restricted cash, at the beginning of the period
13,471
Cash, cash equivalents and restricted cash, at the end of the period
36,261
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Maturities of investments$42,339K Net cash provided byinvesting activities$37,470K Canceled cashflow$4,869K Net change in cash,cash equivalents and...$22,790K Canceled cashflow$14,680K Purchases of investments$4,842K Purchases of property andequipment$27K Receivables fromcollaboration partners-$5,985K Cash received fromgovernment grants$3,830K Stock-based compensationexpense$2,197K Accrued license fees$1,725K Change in fair value ofconvertible note$1,585K Depreciation expense$1,277K Prepaid expenses andother current assets-$890K Interest expense$875K Other non-currentliabilities$434K Amortization of right-of-useasset$281K Netamortization/accretion on investment...-$210K Loss on disposal ofequipment-$4K Proceeds from exercise ofstock options$238K Net cash used inoperating activities-$12,892K Net cash (used in) /provided by financing...-$1,788K Canceled cashflow$19,293K Canceled cashflow$238K Net loss-$23,824K Payments of deferredoffering costs$2,026K Accruals and othercurrent liabilities-$3,236K Accounts payable-$2,139K Deferred revenue-$1,850K Operating leaseliabilities-$616K Other long-termassets$520K